Q-omics provides the consensus-scored BCL7B profile across patient tissues and cancer cell-line models. BCL7B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BCL7B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, BCL7B RNA expression shows 19,082 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where BCL7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL7B survival associations across molecular data types. BCL7B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL7B RNA expression–survival associations across cancer types. High BCL7B expression shows unfavorable associations in KICH, LGG, CESC and UVM, but favorable associations in SKCM and SARC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BCL7B RNA expression.
This table summarizes BCL7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCL7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL7B shows lower tumor expression in BLCA and THCA and higher tumor expression in HNSC, LIHC, KIRC and KIRP. The HNSC box plot shows higher BCL7B RNA expression in tumor versus normal tissue (log2 FC = +0.826, t-test p < 0.001).
This table shows molecular features associated with BCL7B in patient tissues and cancer cell lines. In patient samples, BCL7B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
